COLLEGIUM PHARMACEUTICAL, INC (COLL): Results of Operations and Financial Condition
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress – Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Y
How this was made
The 30-second read
Why it matters
Traders can reprice 2026 revenue and adjusted EBITDA expectations using the revised guidance ranges, with the key debate centered on whether ADHD growth and AZSTARYS ramp offset pain franchise and authorized-generic pricing pressure.
Market read
Primary earnings-and-guidance disclosure with explicit revised 2026 ranges, plus acquisition integration commentary, making it a direct catalyst for positioning in COLL.
What to watch
GAAP operating expenses rose sharply year over year, and the AZSTARYS revenue is only a partial quarter, so margin and integration benefits may take longer to show up in EBITDA.
Background
SEC Form 8-K Item 2.02 with Exhibit 99.1 reporting Q2 2026 financial results and business updates, including completion of the AZSTARYS acquisition and full-year 2026 guidance updates.
Ticker impact
Collegium reported Q2 2026 results and updated full-year guidance, including raising AZSTARYS revenue and adjusted EBITDA while lowering Nucynta AG-driven product revenue assumptions.
Near-term volatility likely around the guidance ranges, with upside bias if investors focus on ADHD growth and AZSTARYS ramp despite pain franchise pricing pressure.
The filing is a primary disclosure (8-K with exhibit) containing specific quarterly results and explicit revised 2026 guidance ranges, which typically drives immediate repricing for revenue and EBITDA expectations.
Market effects
Biopharma ADHD and pain franchise demand signals may influence read-across sentiment for CNS-focused specialty pharma commercial execution.
Limited direct regional impact beyond Massachusetts HQ relocation and local investor attention.
Primarily US commercial and guidance-driven; limited direct global catalyst beyond investor sentiment in specialty pharma.
Counterpoint
The pain portfolio decline and authorized-generic pricing weakness could dominate the narrative if investors discount AZSTARYS ramp as not yet fully reflected in the raised ranges.
Key entities
- companyCollegium Pharmaceutical, Inc.
Nasdaq-listed biopharmaceutical company reporting Q2 2026 results and updated 2026 guidance in an SEC 8-K.
- productAZSTARYS
ADHD medicine acquired in May 2026; guidance raised for AZSTARYS revenue and net product lines.
- productJORNAY PM
ADHD medicine showing strong Q2 growth, including record-high prescriptions and prescriber adoption.
- productNucynta franchise (authorized generic)
Pain franchise pressure cited as lower-than-expected AG net pricing driving decreases in product revenues and adjusted EBITDA guidance.
